PL2317324T3 - Sposób identyfikacji podmiotu objętego ryzykiem rozwinięcia niewydolności serca poprzez określenie poziomu galektyny-3 lub trombospondyny-2 - Google Patents
Sposób identyfikacji podmiotu objętego ryzykiem rozwinięcia niewydolności serca poprzez określenie poziomu galektyny-3 lub trombospondyny-2Info
- Publication number
- PL2317324T3 PL2317324T3 PL10186331T PL10186331T PL2317324T3 PL 2317324 T3 PL2317324 T3 PL 2317324T3 PL 10186331 T PL10186331 T PL 10186331T PL 10186331 T PL10186331 T PL 10186331T PL 2317324 T3 PL2317324 T3 PL 2317324T3
- Authority
- PL
- Poland
- Prior art keywords
- level
- risk
- subject
- determining
- galectin
- Prior art date
Links
- 102000000802 Galectin 3 Human genes 0.000 title abstract 2
- 108010001517 Galectin 3 Proteins 0.000 title abstract 2
- 102100029529 Thrombospondin-2 Human genes 0.000 title abstract 2
- 108010060887 thrombospondin 2 Proteins 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title 1
- 239000003550 marker Substances 0.000 abstract 3
- 230000009787 cardiac fibrosis Effects 0.000 abstract 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4724—Lectins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/321—Arterial hypertension
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03078161A EP1522857A1 (en) | 2003-10-09 | 2003-10-09 | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| EP04765681A EP1682907B1 (en) | 2003-10-09 | 2004-09-27 | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| EP10186331.4A EP2317324B1 (en) | 2003-10-09 | 2004-09-27 | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2317324T3 true PL2317324T3 (pl) | 2015-10-30 |
Family
ID=34306912
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10186331T PL2317324T3 (pl) | 2003-10-09 | 2004-09-27 | Sposób identyfikacji podmiotu objętego ryzykiem rozwinięcia niewydolności serca poprzez określenie poziomu galektyny-3 lub trombospondyny-2 |
| PL04765681T PL1682907T3 (pl) | 2003-10-09 | 2004-09-27 | Metoda identyfikacji podmiotu objętego ryzykiem rozwinięcia niewydolności serca poprzez określenie poziomu galektyny-3 lub trombospondyny-2 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04765681T PL1682907T3 (pl) | 2003-10-09 | 2004-09-27 | Metoda identyfikacji podmiotu objętego ryzykiem rozwinięcia niewydolności serca poprzez określenie poziomu galektyny-3 lub trombospondyny-2 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US7888137B2 (enExample) |
| EP (4) | EP1522857A1 (enExample) |
| JP (5) | JP4840744B2 (enExample) |
| CN (2) | CN102998458B (enExample) |
| AT (1) | ATE532073T1 (enExample) |
| AU (2) | AU2004284496C1 (enExample) |
| CA (2) | CA2542033C (enExample) |
| CY (2) | CY1112359T1 (enExample) |
| DK (2) | DK2317324T3 (enExample) |
| ES (2) | ES2530567T3 (enExample) |
| PL (2) | PL2317324T3 (enExample) |
| PT (2) | PT2317324E (enExample) |
| SI (2) | SI1682907T1 (enExample) |
| WO (1) | WO2005040817A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| JP2010504089A (ja) | 2006-09-25 | 2010-02-12 | ユニフェルジテイト・マーストリヒト | 心不全を発生させる危険がある被検者を診断および／または処置するための手段および方法 |
| EP2109688A4 (en) * | 2007-01-23 | 2010-02-17 | Univ Virginia | GALECTIN-3 BINDING PROTEIN AS BIOMARKER FOR HEART CIRCULATION DISEASES |
| ATE534912T1 (de) * | 2007-09-17 | 2011-12-15 | Bg Medicine Inc | Beurteilung des risikos von kongestiver herzinsuffizienz bei patienten, die mit einem peroxisom-proliferator-aktivator-rezeptor-gamma agonisten oder einem thiazolidindion behandelt werden oder möglicherweise damit behandelt werden sollen |
| BRPI0919975A2 (pt) * | 2008-10-29 | 2015-12-15 | Bg Medicine Inc | imunoensaio para galectina-3 |
| EA201270316A1 (ru) * | 2009-08-25 | 2012-09-28 | БиДжи МЕДИСИН, ИНК. | Галектин-3 и сердечная ресинхронизирующая терапия |
| EP2588111A1 (en) * | 2010-07-02 | 2013-05-08 | BG Medicine, Inc. | Statin therapy monitored by galectin- 3 measurement |
| US8703433B2 (en) * | 2010-10-18 | 2014-04-22 | Hideaki Hara | Marker for amyotrophic lateral sclerosis, and use thereof |
| EP2460890A1 (en) | 2010-12-01 | 2012-06-06 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases |
| US20120220671A1 (en) * | 2011-01-31 | 2012-08-30 | Bg Medicine, Inc. | Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome |
| CN103718046B (zh) | 2011-03-17 | 2016-10-12 | 重症监护诊断股份有限公司 | 预测不良临床结果的风险的方法 |
| AR086543A1 (es) * | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica |
| KR20140067173A (ko) * | 2011-12-08 | 2014-06-03 | 이삭 엘리아스 | 혈장사혈에 의한 갈렉틴-3 레벨의 감소 |
| WO2014052803A2 (en) * | 2012-09-27 | 2014-04-03 | Siemens Healthcare Diagnostics Inc. | Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension |
| EP2919802A4 (en) * | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| AU2016207734A1 (en) | 2015-01-18 | 2017-08-03 | Diasorin S.P.A. | Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker |
| US10688565B2 (en) * | 2015-05-28 | 2020-06-23 | Kyocera Corporation | Cutting tool |
| CN112553335A (zh) * | 2020-12-17 | 2021-03-26 | 核工业总医院 | 肾细胞癌生物标志物及其应用 |
| US20230279120A1 (en) * | 2021-11-09 | 2023-09-07 | Truebinding, Inc. | Methods of treating or inhibiting cardiovascular diseases |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4632901A (en) * | 1984-05-11 | 1986-12-30 | Hybritech Incorporated | Method and apparatus for immunoassays |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) * | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| AU2684488A (en) * | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
| US20010051350A1 (en) * | 1995-05-02 | 2001-12-13 | Albert Nazareth | Diagnostic detection device and method |
| BE1010935A7 (nl) * | 1997-02-19 | 1999-03-02 | Delanghe Joris Richard Siegfri | Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen. |
| US6210976B1 (en) * | 1997-06-10 | 2001-04-03 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| US20060166276A1 (en) * | 1997-09-05 | 2006-07-27 | Lung Health Diagnostics Pty Ltd | Method of diagnosis and agents useful for same |
| EP1018018B1 (en) * | 1997-09-05 | 2010-08-04 | Southern Medical Diagnostics Pty Ltd | A method of diagnosis |
| CA2306751C (en) * | 1997-10-24 | 2006-12-12 | Shionogi & Co., Ltd. | Method for inhibiting degradation of natriuretic peptides and improved method for measuring natgriuretic peptides with the use of the same |
| BR9909422A (pt) * | 1998-04-02 | 2001-09-11 | Genentech Inc | Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico |
| ATE373826T1 (de) * | 1999-01-29 | 2007-10-15 | Roche Diagnostics Gmbh | Verfahren zum nachweis von n-terminalem probnp |
| AU3704500A (en) * | 1999-02-19 | 2001-01-22 | University Of Iowa Research Foundation, The | Diagnostics and therapeutics for arterial wall disruptive disorders |
| AU6794700A (en) * | 1999-08-20 | 2001-03-19 | Board Of Regents, The University Of Texas System | Methods and compositions relating to hdac 4 and 5 regulation of cardiac gene expression |
| EP1290217A2 (en) | 2000-02-04 | 2003-03-12 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| EP1358347A2 (en) | 2000-04-05 | 2003-11-05 | Incyte Genomics, Inc. | Genes expressed in foam cell differentiation |
| KR100395254B1 (ko) * | 2000-10-30 | 2003-08-21 | (주)자리타 바이오텍 | 종양 발생 예측 키트 |
| AU2002220266A1 (en) * | 2000-11-09 | 2002-05-21 | Millennium Pharmaceuticals, Inc. | Methods for the identification and the treatment of cardiovascular disease |
| WO2002038794A2 (en) * | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| CA2431861A1 (en) * | 2000-12-08 | 2002-06-13 | Curagen Corporation | Method of detecting and treating tuberous sclerosis complex associated disorders |
| JP4035562B2 (ja) * | 2001-01-31 | 2008-01-23 | 国立大学法人富山大学 | ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット |
| US7041449B2 (en) | 2001-03-19 | 2006-05-09 | Wisconsin Alumni Research Foundation | Methods of screening for compounds that inhibit expression of biomarker sequences differentially expressed with age in mice |
| US20060019235A1 (en) | 2001-07-02 | 2006-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Molecular and functional profiling using a cellular microarray |
| US7447594B2 (en) | 2001-07-10 | 2008-11-04 | Ocimum Biosolutions, Inc. | Molecular cardiotoxicology modeling |
| US20030099958A1 (en) * | 2001-09-05 | 2003-05-29 | Vitivity, Inc. | Diagnosis and treatment of vascular disease |
| GB0124145D0 (en) | 2001-10-08 | 2001-11-28 | Bayer Ag | Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease |
| US20060141493A1 (en) | 2001-11-09 | 2006-06-29 | Duke University Office Of Science And Technology | Atherosclerotic phenotype determinative genes and methods for using the same |
| SI1509618T1 (sl) * | 2002-05-13 | 2009-02-28 | Arexis Ab | Avtoimunska stanja in defekti NADPH oksidaze |
| WO2004038376A2 (en) | 2002-10-24 | 2004-05-06 | Duke University | Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications |
| CA2505416A1 (en) | 2002-11-21 | 2004-06-10 | Wyeth | Methods for diagnosing rcc and other solid tumors |
| EP1431399A1 (en) * | 2002-12-20 | 2004-06-23 | Clinigenetics | Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions |
| US6889083B2 (en) * | 2003-04-21 | 2005-05-03 | Medtronic, Inc. | Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes |
| US20070105105A1 (en) | 2003-05-23 | 2007-05-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| WO2004111654A2 (en) | 2003-06-06 | 2004-12-23 | Ciphergen Biosystems, Inc. | Serum biomarkers in ischaemic heart disease |
| US20050106100A1 (en) | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| EP1560025A3 (en) * | 2003-10-03 | 2011-09-07 | F. Hoffmann-La Roche AG | Specific markers for diabetes |
| EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| DE10347436B4 (de) * | 2003-10-13 | 2007-08-02 | Johann Wolfgang Goethe-Universität Frankfurt am Main | In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP) |
| WO2005070446A1 (en) | 2004-01-15 | 2005-08-04 | Scios Inc. | Method for treating cardiac remodeling following myocardial injury |
| WO2006026074A2 (en) | 2004-08-04 | 2006-03-09 | Duke University | Atherosclerotic phenotype determinative genes and methods for using the same |
| WO2006083986A2 (en) | 2005-02-01 | 2006-08-10 | Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services | Biomarkers for tissue status |
| WO2006102497A2 (en) | 2005-03-22 | 2006-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease |
| US7632634B2 (en) | 2005-04-15 | 2009-12-15 | University Of Maryland Biotechnology Institute | Method and assay for early diagnosis of prostate cancer |
| US9592970B2 (en) * | 2008-07-17 | 2017-03-14 | Toby D. Henderson | Robotic gantry with end effector for product lifting |
| BRPI0919975A2 (pt) * | 2008-10-29 | 2015-12-15 | Bg Medicine Inc | imunoensaio para galectina-3 |
| EA201270316A1 (ru) * | 2009-08-25 | 2012-09-28 | БиДжи МЕДИСИН, ИНК. | Галектин-3 и сердечная ресинхронизирующая терапия |
-
2003
- 2003-10-09 EP EP03078161A patent/EP1522857A1/en not_active Withdrawn
-
2004
- 2004-09-27 CN CN201210321227.7A patent/CN102998458B/zh not_active Expired - Fee Related
- 2004-09-27 DK DK10186331.4T patent/DK2317324T3/en active
- 2004-09-27 EP EP10186331.4A patent/EP2317324B1/en not_active Expired - Lifetime
- 2004-09-27 PL PL10186331T patent/PL2317324T3/pl unknown
- 2004-09-27 AT AT04765681T patent/ATE532073T1/de active
- 2004-09-27 SI SI200431813T patent/SI1682907T1/sl unknown
- 2004-09-27 ES ES10186331T patent/ES2530567T3/es not_active Expired - Lifetime
- 2004-09-27 PT PT101863314T patent/PT2317324E/pt unknown
- 2004-09-27 DK DK04765681.4T patent/DK1682907T3/da active
- 2004-09-27 SI SI200432221T patent/SI2317324T1/sl unknown
- 2004-09-27 US US10/575,745 patent/US7888137B2/en active Active
- 2004-09-27 EP EP04765681A patent/EP1682907B1/en not_active Expired - Lifetime
- 2004-09-27 PT PT04765681T patent/PT1682907E/pt unknown
- 2004-09-27 PL PL04765681T patent/PL1682907T3/pl unknown
- 2004-09-27 WO PCT/EP2004/010879 patent/WO2005040817A1/en not_active Ceased
- 2004-09-27 CN CN2004800332637A patent/CN1879022B/zh not_active Expired - Fee Related
- 2004-09-27 ES ES04765681T patent/ES2377012T3/es not_active Expired - Lifetime
- 2004-09-27 CA CA2542033A patent/CA2542033C/en not_active Expired - Lifetime
- 2004-09-27 JP JP2006530040A patent/JP4840744B2/ja not_active Expired - Fee Related
- 2004-09-27 CA CA2842308A patent/CA2842308A1/en not_active Abandoned
- 2004-09-27 EP EP14192739.2A patent/EP2919012A1/en not_active Withdrawn
- 2004-09-27 AU AU2004284496A patent/AU2004284496C1/en not_active Ceased
-
2009
- 2009-10-19 AU AU2009227844A patent/AU2009227844B2/en not_active Ceased
-
2010
- 2010-07-26 JP JP2010167334A patent/JP2010279378A/ja not_active Withdrawn
- 2010-10-28 US US12/914,329 patent/US8084276B2/en not_active Expired - Fee Related
-
2011
- 2011-04-12 JP JP2011088342A patent/JP5580774B2/ja not_active Expired - Lifetime
- 2011-11-23 US US13/304,145 patent/US20120220532A1/en not_active Abandoned
-
2012
- 2012-02-01 CY CY20121100108T patent/CY1112359T1/el unknown
-
2013
- 2013-03-08 US US13/791,350 patent/US20130189716A1/en not_active Abandoned
-
2014
- 2014-02-06 JP JP2014021394A patent/JP5789009B2/ja not_active Expired - Lifetime
- 2014-05-05 US US14/269,707 patent/US20150037353A1/en not_active Abandoned
-
2015
- 2015-02-12 CY CY20151100136T patent/CY1116147T1/el unknown
- 2015-04-13 JP JP2015081540A patent/JP2015171365A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2317324T1 (sl) | Postopek identifikacije subjekta, ki mu grozi nevarnost srčne odpovedi z ugotavljanjem nivoja galektina-3 ali trombospondina-2 | |
| DK1734368T3 (da) | Annexin-autoantistoffer anvendt som markörer for lungecancer | |
| AU2002902A (en) | Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrinas a marker | |
| EP2306192A3 (en) | Risk Markers For Cardiovascular Disease | |
| ATE111228T1 (de) | Verfahren zur überwachung des kollagenabbaus. | |
| EP2293075A3 (en) | Method for diagnosing neuro-degenerative disease | |
| ATE545032T1 (de) | Diagnose von herz-kreislauf-erkrankung | |
| WO2003065875A3 (en) | Method and test strips for the measurement of fat loss during weight loss programs | |
| WO2000070340A3 (en) | Materials and methods relating to disease diagnosis | |
| AU2003265768A1 (en) | Automated framework for the analysis of biological data | |
| DK0507831T3 (da) | Fremgangsmåde til detektion af knogle- og bindevævssygdomme hos mennesker og dyr | |
| EP1162461B8 (en) | Automated method for detecting, quantifying and monitoring exogenous hemoglobin in whole blood, plasma and serum | |
| CY1105025T1 (el) | Αναλυση λεπτινης βασιζομενη στην ανιχνευση εκφρασης ang-2 | |
| EP1132483A3 (en) | Method for diagnosing schizophrenia using objective indices | |
| CA2243372A1 (en) | Methods of diagnosing muscle damage | |
| EP1612559A4 (en) | METHOD FOR EVALUATING THE ANTIOXIDATION POTENTIAL OF A BIOLOGICAL SAMPLE | |
| WO2003099107A3 (en) | Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient | |
| DE50303798D1 (de) | Vorrichtung, um in einem Zielgebiet eines menschlichen oder tierischen Körpers einen künstlichen isolierten Kreislauf zu etablieren | |
| DE60230988D1 (de) | Proteine in der diabetes-proteomanalyse | |
| WO2006117688A3 (en) | Diagnosis of heart failure | |
| WO2005005957A3 (en) | Method of detecting cancer using delta-catenin | |
| WO2003068958A1 (fr) | Procede d'analyse d'un acide nucleique specifiant un gene presentant une modification de son niveau d'expression liee a la schizophrenie | |
| CA2297361A1 (en) | Methods of diagnosing muscle damage | |
| DE60326269D1 (de) | Verfahren zur detektion von prpsc unter verwendung von gruppe ii aminoglykosid antibiotika | |
| WO2005060627A3 (en) | Methods of assessing the risk of non-traumatic bone fracture |